MOTS-c + NAD-IV: What the Evidence Shows

MOTS-c and NAD-IV get paired as a "mitochondrial stack". The evidence behind each half is thin, and the pair itself has never been tested in people. This page sets out what is known, what is not, and where the law stands.

What this stack is

MOTS-c is a short peptide, a chain of just 16 amino acids. Its code sits in your mitochondria's own DNA, though the cell builds it outside them. Mitochondria are the main energy centres of your cells. The peptide acts as a signal, and skeletal muscle appears to be its main target. You can read more on our MOTS-c page.

NAD-IV means NAD+ given straight into a vein by drip. NAD+ is short for nicotinamide adenine dinucleotide. It is a helper molecule your cells need to make energy. It also feeds enzymes involved in DNA repair.

The pitch for the pair is simple. MOTS-c is the signal and NAD+ is the fuel. That is a theory, not a result. FDA found no human data for MOTS-c by any route, so no one has tested the two together in people.

What the evidence shows for MOTS-c

Almost everything we know comes from animal and cell studies. In the first major paper, MOTS-c prevented diet-induced obesity and insulin resistance in rodent (mouse) studies. Insulin resistance means your cells respond poorly to insulin. The peptide worked partly by switching on AMPK, an energy sensor inside cells.

A later study found that MOTS-c improved physical performance in young, middle-aged and old rodent (mouse) groups. In old rodents (mice), treatment started late in life, three times a week, still raised physical capacity.

One finding does come from people. Exercise raises the MOTS-c your own body makes, in muscle and in blood. That is your own peptide, not an injected one.

FDA reviewed this research for its July 2026 advisory meeting. It noted the animal work was limited to rodent models and never tested how effects change with dose. It also said the molecules MOTS-c acts on are still unknown. On people, FDA was blunt: "FDA has not identified, any clinical studies or human exposure data for MOTS-c via any route of administration."

There is one more problem. A lab study found MOTS-c breaks down quickly in human blood. FDA said it is unclear whether an injection can reach active levels at all.

What the evidence shows for NAD-IV

The human data on IV NAD+ is small. One study tracked it closely. It used eight healthy men aged 30 to 55, with three more given saline. Each got 750 mg of NAD+ dripped in over six hours.

The results surprised the researchers. Blood NAD+ did not rise at all for the first two hours. By the end of the drip it had risen by about 400%. It was still raised two hours after the drip stopped. One author ran a clinic that uses IV NAD+ as a therapy.

A 2026 study looked back at clinic records instead. Six people got 500 mg of NAD+ by drip on four days in a row. All six reported moderate to severe symptoms during the drip. These included cramping, diarrhoea, nausea, vomiting, a raised heart rate and chest pressure. Their symptoms stopped once each drip ended. The authors worked for the company that ran the clinic.

A 2026 review pulled the human evidence together. It found mostly small uncontrolled studies, observational studies and case reports. Its verdict was plain: the evidence is "insufficient to support routine clinical or wellness use." The review also covers other small, uncontrolled reports. One 2018 pilot gave 1,000 mg a day for six days to eight adults aged 70 to 80.

What about the claim that NAD+ falls with age? One study of adults aged 20 to 87 found lower NAD+ in the blood plasma of older people. Yet newer large data found whole-blood NAD+ did not track age once disease burden was accounted for. The question is still open.

What is and isn't known

This page used to give a week-by-week guide to results. That guide had no human data behind it, so it is gone. Here is the honest version.

What is known. MOTS-c changes how rodents (mice) handle blood sugar and body fat. Exercise raises your own MOTS-c. A six-hour IV drip of NAD+ raised blood NAD+ in a small group of men. Self-paced drips of about 97 minutes came with strong short-term side effects in a small clinic study.

What isn't known. No one knows whether injected MOTS-c does anything in people, or whether it is safe. No one knows how the body absorbs or clears injected MOTS-c. For IV NAD+, the best dose, the lasting benefit and the long-term safety are all unknown. No timeline of effects exists for either compound or for the pair.

Dosing: what has and hasn't been studied

No human dose of MOTS-c has been studied. FDA found no clinical studies giving pharmacokinetic data, meaning data on how the body absorbs and clears a drug. With no clinical studies at all, no MOTS-c schedule rests on a human trial.

For IV NAD+, the two studies covered here describe what was given, not a proven plan. One gave 750 mg once, over six hours. The other gave 500 mg a day for four days. The 750 mg dose was chosen because it was a common clinic regimen. The 2026 review says the best dose cannot yet be set.

Side effects and safety

MOTS-c. FDA states that the safety risks of MOTS-c in humans are unknown. It could not rule out immunogenicity, especially when the peptide is injected. Immunogenicity means your immune system reacting against the substance itself. FDA's adverse event database held no MOTS-c reports. But FDA also notes that compounders generally do not report adverse events to it. So no reports is not the same as no harm.

In rodent (mouse) studies, MOTS-c changed insulin sensitivity. With no human data at all, nobody knows how it mixes with glucose-lowering medicines in people.

NAD-IV. Reported side effects include nausea, cramping, flushing and chest discomfort. The review says they occur particularly at faster drip rates. The six-hour study, at about 2 mg a minute, saw no adverse events. In the clinic study, a 30-day check found a drop in HDL, the "good" cholesterol, though levels stayed in the normal range. Long-term safety data are lacking.

Together. There is no safety data on the pair, because there is none on MOTS-c in people. The six-hour NAD+ study left out people with a history of liver or kidney failure. Both NAD+ studies screened people before any drip. In the clinic study, a nurse practitioner cleared each person first.

Legal status

This section covers the US only. Rules differ in other countries, and we have not checked them here.

MOTS-c. MOTS-c is not part of any FDA-approved drug. FDA runs a list of bulk substances that pharmacies may use to compound drugs, known as the 503A bulks list. MOTS-c is not on that list. For its July 2026 meeting, FDA proposed not adding MOTS-c to the list. The National Community Pharmacists Association reported that the advisory committee then voted to recommend adding MOTS-c. The vote is advisory and does not bind FDA. FDA's meeting page lists no minutes or voting record.

If you compete in tested sport, one more point matters. FDA's briefing notes that MOTS-c is listed as prohibited in the Global DRO database, which draws on the 2024 World Anti-Doping Agency list.

NAD+. NAD+ is not on the 503A bulks list either. FDA lists it in Category 1, which covers substances still under evaluation. A salt form, beta-NAD disodium salt trihydrate, sits in Category 3, for substances nominated without adequate support.

Sourcing and quality

FDA called MOTS-c "not well-characterized" as a raw material. It found no published data on its impurities, clumping or endotoxins. Endotoxins are toxins shed by bacteria. The one nomination included no certificate of analysis for the free-base form of MOTS-c. A certificate of analysis is the lab report on identity and purity. The certificate it did include, for MOTS-c acetate, had no results for impurities, clumping or endotoxins. Clumps of peptide, called aggregates, are a known risk factor for immune reactions.

Freeze-dried MOTS-c is expected to stay stable below -20°C, kept dry and away from light. In the clinic study, nurses mixed 500 mg of freeze-dried NAD+ and diluted it in 500 mL of saline.

If you work with a freeze-dried research vial, the reconstitution calculator handles the water and concentration arithmetic. It cannot tell you what dose is safe, because for MOTS-c no one knows.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice.